Isomorphic Labs raises a $2.1 billion Series B

Background

Making a new medicine is slow, expensive and failure-prone. A discovery team usually starts from a biological target — a protein or pathway implicated in a disease — and then searches an enormous space of possible molecules for one that binds it, survives long enough in the body to be useful, and can be manufactured. Most candidates that look promising in the laboratory do not survive later testing. Computational drug design tries to narrow that search: machine learning models are trained on chemical and biological data to propose structures and to estimate, before anything is synthesised, which ones are worth making.

Isomorphic Labs works in this area, applying computation to drug design. Before this round, Alphabet and GV were already backers of the company ^[1].

What was announced

On 12 May 2026 the company announced that it had raised $2.1 billion in Series B funding ^[1]. The round was led by Thrive Capital ^[1]. Existing backers Alphabet and GV participated ^[1], and new investors joined, including MGX, Temasek, CapitalG and the UK Sovereign AI Fund ^[1].

Key details: where the money is meant to go

The company said the money would scale its business globally and progress its drug candidate pipeline ^[1]. It tied the raise to its AI drug design engine, IsoDDE ^[1]. Isomorphic Labs also said the round significantly expands its global capital base ^[1].

Alongside the financing, the company described its aim of applying IsoDDE across multiple therapeutic areas and drug modalities ^[1]. A therapeutic area is a broad category of disease rather than a single condition; a drug modality is the physical form a therapy takes — a small synthetic molecule, an antibody, a nucleic acid, a cell — each with different manufacturing, delivery and dosing requirements. Working "across" areas and modalities therefore means more than repeating one kind of programme in more places: it means using the same design engine on different kinds of chemistry and different kinds of disease.

Why a Series B matters

In venture financing, "Series B" conventionally denotes a company's second major priced equity round, following seed and Series A money. Rounds at this stage are usually intended to turn an early organisation into one that can run several programmes at once: hiring, building shared infrastructure, and carrying research far enough to test it properly.

For Isomorphic Labs the round has two visible features. First, it combines a new lead investor with backers who were already involved, and adds a further group of new investors alongside them ^[1]. Second, the stated use of proceeds is organisational and pipeline work — global scaling and progress on drug candidates — rather than a single named transaction ^[1]. The size of the round, as the company gives it, is $2.1 billion ^[1].

What it changes, and what it does not

Funding changes resources: how many programmes can run at once, how large the team can be, and whether the company can operate in more than one place. The company put global expansion, pipeline progress and a larger global capital base at the centre of its announcement ^[1].

Funding does not settle the scientific question underneath. Whether computationally designed candidate molecules hold up in clinical testing is decided by the trials, not by the size of a financing round. The company's stated aim of applying IsoDDE across multiple therapeutic areas and drug modalities is, in effect, a plan to test that question more widely — on more kinds of disease and more kinds of molecule — than a single programme would allow ^[1].